The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma

por Beard, S M, Lorigan, P C, Sampson, F C
Publicado 2000

TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes

por Katerinaki, E, Evans, G S, Lorigan, P C, MacNeil, S
Publicado 2003

Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up

por Nahm, S.H., Rembielak, A., Peach, H., Lorigan, P.C.
Publicado 2021

Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis

por Sharma, S, Jagdev, S, Coleman, R E, Hancock, B W, Lorigan, P C
Publicado 1999

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactin...

por Dobson, L S, Lorigan, P C, Coleman, R E, Hancock, B W
Publicado 2000

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

por Zekri, J M, Hough, R E, Davies, J M, Molife, R, Hancock, B W, Lorigan, P C
Publicado 2003

Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

por Gillespie, A. M., Lorigan, P. C., Radstone, C. R., Waterhouse, J. C., Coleman, R. E., Hancock, B. W.
Publicado 1997

Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma

por Hough, R E, Goepel, J R, Alcock, H E, Hancock, B W, Lorigan, P C, Hammond, D W
Publicado 2001

High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia

por El-Helw, L M, Seckl, M J, Haynes, R, Evans, L S, Lorigan, P C, Long, J, Kanfer, E J, Newlands, E S, Hancock, B W
Publicado 2005

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients

por Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M.R., Lee, R.J., Garner, G., Dhomen, N., Lorigan, P.C., Marais, R.
Publicado 2018

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

por Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Publicado 2017